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Abstract: Acute kidney injury (AKI) is an independent risk factor for morbidity and mortality. 
This review provides essential information for the diagnosis and management of AKI. Blood 
urea nitrogen and serum creatinine are used for the diagnosis of AKI. The review also focuses on 
recent studies on the diagnosis of AKI using the RIFLE (R-renal risk, I-injury, F-failure, L-loss 
of kidney function, E-end stage kidney disease) and Acute Kidney Injury Network criteria, and 
serum and urine AKI biomarkers. Dialysis is the only Food and Drug Administration-approved 
therapy for AKI. Recent studies on the dose of dialysis in AKI are reviewed.
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Diagnosis of acute kidney injury
Acute kidney injury (AKI) is characterized by a sudden impairment of kidney func-
tion occurring over a period of hours to days. A diagnosis of AKI is currently made 
on the basis of the presence of increased serum creatinine and/or blood urea nitrogen 
(BUN) levels and/or a decreased urine output, despite their well-known limitations. 
It should be noted that changes in BUN and serum creatinine may represent not only 
renal injury, but also normal responses of the kidney to extracellular volume depletion 
or decreased renal blood flow.
Recent developments in the diagnosis of AKI include 1) use of the RIFLE (R-renal 
risk, I-injury, F-failure, L-loss of kidney function, E-end stage kidney disease [ESKD]) 
and AKIN (Acute Kidney Injury Network) criteria and 2) use of biomarkers of AKI.
RIFLe or AKIN criteria (Table 1)
Small increases of serum creatinine levels in hospitalized patients are associated with 
substantial morbidity and mortality.1 The Acute Dialysis Quality Initiative developed 
a consensus definition and classification of AKI based on creatinine increase and 
decrease in glomerular filtration rate (GFR) or urine output: the RIFLE criteria. More 
recently, the RIFLE criteria were modified by the AKIN. The criteria are identical 
to the first three stages of RIFLE, with the exception of a shorter time frame of AKI 
within 48 hours, and a lower creatinine threshold of greater than 0.3 mg/dL from 
baseline to peak value (Table 1). The prognostic values of the RIFLE and AKIN 
criteria have been validated for in-hospital mortality in numerous studies including 
cardiothoracic surgery, trauma, or critically ill patients and they provide a uniform 
definition of AKI.1−4 A new study comparing the diagnostic and prognostic factors of 
the RIFLE and AKIN classifications for AKI after cardiac surgery showed that both 
are equally useful in diagnosis and accurate in prognosis.5International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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Biomarkers of AKI
Serum creatinine is the most widely used parameter to 
assess renal function. Unfortunately, serum creatinine is 
not a very reliable marker of AKI in many patients. There 
are many renal and non-renal factors that influence serum 
creatinine independent of kidney function. For example, 
creatinine generation is proportional to muscle mass and 
is affected by age, gender, body weight, and diet.6−8 The 
most important limitation of serum creatinine is the delayed 
increase of serum creatinine levels after actual changes in 
GFR. In addition, serum creatinine levels may vary with 
intravascular volume expansion or depletion and with 
hemodynamic changes, regardless of renal function. These 
problems often lead to delayed recognition of AKI and late 
initiation of treatment in especially intensive care unit (ICU) 
patients and elderly.9
Many biomarkers have been widely studied for use 
in the diagnosis of AKI because serum creatinine is an 
imperfect marker for the early and accurate diagnosis of 
AKI. A biomarker that is released into the blood or urine 
from the injured kidney soon after AKI may be an earlier 
marker of AKI than serum creatinine. Early diagnosis of 
AKI may result in more optimal dosing of antibiotics, 
avoidance of nephrotoxic agents, and earlier nephrology 
consultation. The most promising early biomarkers of AKI 
are interleukin-18 (IL-18), neutrophil gelatinase-associated 
lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and 
cystatin C.
In addition to being a mediator of AKI, IL-18 is also a 
biomarker of AKI. IL-18 is increased in the urine in mice 
with AKI.10,11 Urine IL-18 is increased in patients with AKI 
compared to other kidney diseases and in renal transplant 
patients with delayed graft function.12,13 Urine IL-18 increases 
48 hours before a 50% increase in serum creatinine in 
  critically ill adults with acute respiratory distress syndrome,14 
children with AKI in the ICU,15 children that develop AKI 
post cardiopulmonary bypass,16 and in adults with contrast 
nephropathy.17
NGAL is a small protein of the lipocalin superfamily and 
is expressed by renal tubular cells.18 NGAL protein increases 
in the kidney, in the urine in early ischemic AKI in rats and 
mice,19 and in the early stage of cisplatin-induced AKI.20 
NGAL increases in the urine before serum creatinine in chil-
dren and adults with AKI post cardiopulmonary bypass,21,22 
children with AKI in the ICU,23,24 and adults and children with 
contrast nephropathy.25,26 Urine and plasma NGAL predicts 
AKI in critically ill adults.27,28 Plasma NGAL concentrations 
obtained during surgery are highly associated with postop-
erative AKI in patients undergoing liver transplantation.29 
A more recent meta-analysis of 12 adults and seven children 
studies including cardiac surgery, contrast nephropathy, and 
critically ill patients demonstrated that plasma and urine 
NGAL levels appear to be of diagnostic and prognostic 
value for AKI.30
KIM-1 is an epithelial cell adhesion molecule that 
is expressed at a low level in normal kidney. KIM-1 is 
increased in the kidney in ischemic AKI in rats and mice.31,32 
Urinary KIM-1 is increased in patients with acute tubular 
necrosis (ATN),33 and is a predictor of graft loss in kidney 
transplant patients.34 More recently, a rapid KIM-1 urine 
dipstick was developed for the early detection of kidney 
injury.35 In another study, it has been shown that a panel 
of urinary biomarkers including NGAL, N-acetyl-β-(D)-
glucosaminidase and KIM-1 may improve the early detection 
of postoperative AKI after cardiac surgery before a rise in 
serum creatinine.36
Table 1 RIFLe and AKIN criteria for diagnosis of AKI
RIFLE criteria (within 7 days)
Class GFR criteria Urine output criteria
R-Risk Creatinine increase × 1.5 or GFR loss . 25% 0.5 , mL/kg/hour × .6 hours 
I-Injury Creatinine increase × 2 or GFR loss . 50% 0.5 , mL/kg/hour × .12 hours
F-Failure Creatinine increase × 3 or GFR loss . 75% or  
creatinine increase .4 mg/dL (acute increase .0.5 mg/dL)
0.3 , mL/kg/hour × .24 hours   
or anuria .12 hours
L-Loss Persistent loss of kidney function .4 weeks
e-eSKD eSKD . 3 months
AKIN criteria (within 48 hours)
Stage Serum creatinine criteria Urine output criteria
1 Creatinine increase × 1.5 or creatinine increase .0.3 mg/dL 0.5 , mL/kg/hour × .6 hours 
2 Creatinine increase × 2 0.5 , mL/kg/hour × .12 hours
3 Creatinine increase × 3 or creatinine increase .4 mg/dL  
(acute increase .0.5 mg/dL)
0.3 , mL/kg/hour × .24 hours 
or anuria .12 hoursInternational Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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Cystatin C is a protein produced by all nucleated cells 
compared to creatinine that is produced by muscle. It is freely 
filtered by the glomerulus.37 Cystatin C is an   earlier marker 
of AKI than serum creatinine in patients with AKI and adults 
post cardiopulmonary bypass.38,39 Serum cystatin C is a more 
accurate marker of GFR than serum creatinine in contrast 
nephropathy,40 liver cirrhosis,41,42 and critically ill adults and 
children.43,44 A more recent study showed that serum cystatin 
C level performs similarly to serum creatinine level, serum 
urea nitrogen level, and urine output for predicting dialysis 
requirement or in-hospital death in patients with AKI.45
Other biomarkers of AKI are fatty acid-binding proteins, 
netrin-1, tubular enzymes, IL-6 and IL-8.
Diagnosis of the cause of AKI
The causes of AKI may be prerenal (Table 2), post renal 
(Table 3), or intrinsic renal (Table 4). An approach to deter-
mining the cause of AKI includes a careful history, physical 
examination, and examination of the urine.
History and physical examination
A careful recording of patient data (vital signs, daily weights, 
records of intake and output, past and current laboratory 
Table 2 Conditions causing prerenal azotemia
Hypovolemia
Hemorrhage
Gastrointestinal losses
Third space
  Burns
  Peritonitis
  Muscle trauma
Renal fluid losses
  Overdiuresis
Impaired cardiac function
Congestive heart failure
Cardiogenic shock
  Acute myocardial infarction
Pericardial tamponade
Massive pulmonary embolism
Systemic vasodilatation
Gram-negative bacteremia
Antihypertensive medications
Anaphylaxis
Cirrhosis
Increased renal vascular resistance
Anesthesia
Surgery
Hepatorenal syndrome
Prostaglandin inhibitors
  NSAIDs
Renal vasoconstricting drugs
  Cyclosporin
Table 3 Conditions causing postrenal azotemia
Urethral obstruction
valves
Stricture
Bladder neck obstruction
Prostatic hypertrophy
Bladder carcinoma
Bladder infection
Functional
  Autonomic neuropathy
  Alpha adrenergic blockers
Bilateral obstruction of ureters (unilateral obstruction in 
solitary kidney)
Intraureteral
  Sulphonamide, uric acid, acyclovir, anti-retroviral agent crystals
  Blood clots
  Stones
  Necrotizing papillitis
extraureteral
  Tumor of cervix, prostate, bladder
  endometriosis
  Periureteral fibrosis
  Accidental ureteral ligation
  Pelvic abscess or hematoma
data, fluid balance, and medication) should be documented. 
Careful analysis of the history to detect causes of AKI like 
administration of non-steroidal anti-inflammatory drugs 
(NSAIDs), diuretics, radiocontrast agents, or antibiotics 
should be performed.
A careful evaluation by the history and physical examina-
tion for causes of prerenal, postrenal, or intrarenal azotemia is 
the most important classical approach to the early diagnosis 
of the cause of AKI.
Prerenal azotemia
The conditions causing prerenal azotemia are listed in 
Table 2. There are four criteria required for a diagnosis of 
prerenal azotemia: 1) an acute rise in BUN and/or serum 
creatinine, 2) a cause of renal hypoperfusion, 3) a bland urine 
sediment (absence of cells and cellular casts) or fractional 
excretion of sodium (FENa) of less than 1%, and 4) the return 
of renal function to normal within 24–48 hours of correction 
of the hypoperfused state.
Postrenal azotemia
Obstruction of urine flow in both ureters, the bladder, or 
urethra or obstruction of a solitary kidney may cause post-
renal AKI. The common causes of postrenal AKI are listed 
in Table 3. The common denominator of acute azotemia in 
this setting is obstruction to the flow of urine. The patient 
most at risk for acute postrenal azotemia is the elderly man 
in whom prostatic hypertrophy or prostatic cancer may lead International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
132
Akcay et al
to complete or partial obstruction to urine flow. A pelvic 
  examination is mandatory in the evaluation of postrenal 
azotemia, because patients with cervical or endometrial 
  carcinoma or   endometriosis may   present with azotemia 
secondary to bilateral ureteral obstruction. Renal ultra-
sonography will detect pelvicalyceal dilatation secondary 
to obstruction in more than 90% of patients.
Intrinsic (intrarenal) AKI
After prerenal and postrenal azotemias have been excluded, the 
diagnosis of intrarenal AKI can be considered (Table 4).
Urinalysis
Microscopy
Assessment of the urinary sediment also is crucial in the 
diagnosis of AKI. An active sediment with renal tubular 
epithelial cells, cellular debris, and “muddy brown” broad 
tubular cell casts supports the diagnosis of ATN. Large 
amounts of urinary protein (.3.0 g/24 hours) and numerous 
red blood cell casts are indicative of AKI secondary to acute 
glomerulonephritis or vasculitis. The absence of cellular 
elements and protein in the urine is most compatible with 
prerenal and postrenal azotemia. An abundance of crystals 
in the urine such as uric acid or oxalate crystals secondary 
to ethylene glycol or methoxyflurane toxicity or crystalluria 
in an AIDS patient being treated with acyclovir or indinavir 
also may provide a clue to the specific cause of the AKI. 
A recent study reviewed the literature from 1960–2009 for 
studies on urine microscopy with sediment examination 
for the differential diagnosis or risk stratification of AKI.46 
The study concluded that urine   microscopy with sediment 
examination has merit for   differentiating ATN from prerenal 
Table 4 Conditions that cause parenchymal (intrinsic) AKI
Vascular
Large vessels
  Bilateral renal artery stenosis
  Bilateral renal vein thrombosis
  Operative arterial cross clamping
Small vessels
  vasculitis
  Atheroembolic disease
  Thrombotic microangiopathies
  Hemolytic uremic syndrome
  Thrombotic thrombocytopenic purpura
  Scleroderma renal crisis
  Malignant hypertension
  Hemolysis, elevated liver enzymes and low platelets syndrome (HeLLP)
Glomerular
Diseases with linear immune complex deposition
  Goodpasture’s syndrome
Diseases with granular immune complex deposition
  Acute postinfectious glomerulonephritis
  Lupus nephritis
  Infective endocarditis
  Immunoglobulin A (IgA) glomerulonephritis
  Henoch-Schonlein purpura
  Membranoproliferative glomerulonephritis
  Cryoglobulinemia
Diseases with few immune deposits (“Pauci-immune”)
  wegener’s granulomatosis
  Polyarteritis nodosa
  Idiopathic crescentic glomerulonephritis
  Churg-Strauss syndrome
Interstitium
Acute allergic interstitial nephritis
Antibiotics
  Beta-lactam antibiotics (penicillins, methicillin, cephalosporins)
  Rifampicin
  Sulphonamides
  erythromycin
  Ciprofloxacin
Diuretics (furosemide, thiazides, chlorthalidone)
Nonsteroidal anti-inflammatory drugs (NSAIDs)
Anticonvulsant drugs (phenytoin, carbamazepine)
Allopurinol
Interstitial nephritis associated with infection, granuloma, crystals
  Streptococcal
  Staphylococcal
  Diphtheria
  Leptospirosis
  Brucellosis
  Legionnaire’s disease
  Toxoplasmosis
  Infectious mononucleosis
  Salmonella typhi
  Tuberculosis
  Sarcoidosis
  Acute uric acid nephropathy eg, tumor lysis syndrome
  Hypercalcemia
  Melamine toxicity
Acute tubular necrosis
Renal ischemia (50% of cases)
  Shock
  Complications of surgery
(Continued)
Table 4 (Continued)
  Hemorrhage
  Trauma
  Gram-negative bacteremia
  Pancreatitis
    Pregnancy (postpartum hemorrhage, abruptio placenta, septic 
abortion)
Nephrotoxic drugs (35% of cases)
    Antibiotics (aminoglycosides, amphotericin, pentamidine, foscarnet, 
acyclovir)
  Antineoplastics (cisplatin, methotrexate)
  Iodine-containing x-ray contrast
  Organic solvents (carbon tetrachloride)
  ethylene glycol (antifreeze)
  Anesthetics (enflurane)
  Acute phosphate nephropathy
endogenous toxins
  Myoglobin due to rhabdomyolysis
  Hemoglobin (incompatible blood transfusion, acute falciparum malaria)
  Uric acid (acute uric acid nephropathy) International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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AKI. Similarly, they found that the presence and number of 
renal tubular epithelial cells and renal tubular epithelial cell 
casts and/or granular casts in the urine sediment may help in 
the diagnosis of ATN and may be useful in predicting more 
severe kidney damage (non-recovery of AKI and need for 
dialysis).46 In a subsequent study, a scoring system based 
on the number of renal tubular epithelial cells and granular 
casts in the urine was developed to evaluate the severity and 
worsening of AKI.47 A urine sediment score of greater than 
or equal to three versus zero on an ATN urinary sediment 
scoring system was a significant predictor of worsening of 
AKI (progressing to a higher AKIN stage [Table 1], dialysis, 
or death) (Table 5).47
Urine biochemistry
Considerable information may be obtained from the assess-
ment of the urinary composition.48,49 A classical study by 
Miller and associates48 evaluated the differences in urinary 
composition between prerenal azotemia and both oliguric 
and nonoliguric AKI. Those differences are summarized 
in Table 6. If   mannitol or a diuretic has been administered 
within a few hours of obtaining the urine for examination, 
the interpretation of the urinary composition is difficult 
because with prerenal azotemia the administration of either of 
these substances may raise the urinary sodium concentration 
and impairs renal   concentrating capacity. FENa is increased 
in ATN, but may be low in   association with AKI caused 
by nonoliguric ATN,   radiocontrast,   hepatorenal syndrome, 
rhabdomyolysis, acute glomerulonephritis, vasculitis, and 
early obstructive uropathy.50
Clinical features of common  
causes of AKI
Sepsis
Sepsis is the most frequent cause of AKI in intensive care 
units.51,52 AKI occurs in approximately 19% of patients with 
moderate sepsis, 23% of patients with severe sepsis, and 51% 
of patients with septic shock.53 The combination of AKI and 
sepsis is associated with more than 80% mortality.52
Nephrotoxins
Nephrotoxins are an important cause of AKI. Some important 
nephrotoxins are aminoglycoside antibiotics, radiocontrast 
media, NSAIDs, cisplatin, and amphotericin B.
The aminoglycosides are major antibiotics in the   treatment 
of serious gram-negative infections. Their increased use and 
potential nephrotoxic risk have made them a   frequent cause 
of AKI. AKI occurs in 10–25% of patients on   aminoglcosides 
even with careful dosing and therapeutic plasma levels. 
Aminoglycoside-induced   nephrotoxicity is characterized by 
slow rises in serum creatinine, tubular necrosis, and marked 
decreases in GFR and in the   ultrafiltration coefficient.
Several factors may predispose to aminoglycoside 
nephrotoxicity. These include advancing age, underlying 
renal disease, volume depletion, hypertension, and recent 
exposure to aminoglycosides or other nephrotoxic drugs. The 
clinical course of aminoglycoside nephrotoxicity is usually 
gradual in onset and is related to the dose and duration of 
drug exposure. Frequently, mild proteinuria, lysozymuria, a 
defect in concentrating ability, and polyuria precede a decline 
in glomerular filtration. Early findings are isothenuria second-
ary to nephrogenic diabetes insipidus and magnesium and 
potassium wasting. Later findings include azotemia.
Cisplatin is a very effective chemotherapeutic agent used 
in a number of malignant tumors. Despite routine use of 
hydration and mannitol, there is still a significant incidence 
of renal failure. Cisplatin nephrotoxicity is cumulative and 
dose dependent.54 A significant and transient increase in BUN 
and serum creatinine is observed in most patients after a 
single dose of 40–100 mg/m2. At a high dose of 100 mg/m2 
given over one week, there is a prolonged renal failure that 
can last up to two years.55
Radiocontrast-induced nephropathy (CIN) has been rec-
ognized to be a cause of AKI with increasing frequency in 
the past few years. The incidence of CIN is about 11.3% using 
the definition of a 25% increase in serum creatinine or an abso-
lute increase in serum creatinine of 0.5 mg/dL.56 Radiocontrast 
agents cause AKI by inducing renal vasoconstriction followed 
by hypoxic tubular injury.57,58 Predisposing factors include age 
Table 5 Scoring system of AKI severity based on number of granular casts and RTe cells in urinary sediment
RTE cells (per HPF) Granular casts (per LPF)
0 (0 Points) 1 to 5 (1 Point) $6 (2 Points)
0 (0 points) 0 1 2
1 to 5 (1 point) 1 2 3
$6 (2 points) 2 3 4
Notes: Values denote total points awarded. A urine sediment score of greater than or equal to three versus zero was a significant predictor of worsening of AKI (progressing 
to a higher AKIN stage [Table 1], dialysis, or death).47 Reproduced from Perazella et al.47
Abbreviations: HPF, high-powered field; LPF, low-powered field; RTE, renal tubular epithelial.International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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(.55 years), prior renal insufficiency, diabetes   mellitus with 
neurovascular complications, proteinuria,   volume depletion, 
acute liver failure, and recent nephrotoxic drug exposure.59 
The onset of renal failure usually is abrupt within 24 hours 
after exposure to contrast media and is characterized by 
oliguria, but it may be nonoliguric.60 Recovery of renal func-
tion generally occurs. However, patients with advanced renal 
failure, particularly diabetic patients with nephropathy, may 
not recover function following contrast-induced AKI and may 
require chronic hemodialysis therapy.
Two recent meta-analyses demonstrated that intravenous 
sodium bicarbonate is better than sodium chloride in prevent-
ing CIN as defined by an increase in serum creatinine of 25% or 
an absolute increase in serum creatinine of 0.5 mg/dL. Intrave-
nous sodium chloride was not different to intravenous sodium 
bicarbonate in preventing the need for renal replacement 
therapy (RRT) or death.56 Prophylactic oral administration 
of the antioxidant acetylcysteine, along with hydration, attenu-
ates the reduction in renal function (defined by an increase in 
serum creatinine of at least 0.5 mg/dL) induced by contrast 
agents in patients with chronic renal insufficiency.61
NSAIDs which are used in the management of pain and 
rheumatic disorders are increasingly recognized as etiologic 
factors in AKI. These substances, which include a large group 
of newer non-steroidal agents, COX-2 inhibitors, as well as 
aspirin and its derivatives, have in common the inhibition 
of prostaglandin synthesis.61 NSAID-induced AKI is due to 
the diminished renal vasodilatory effect of prostaglandins. 
Predisposing factors to NSAID-induced ischemic renal 
dysfunction include diuretic use, elderly age, atherosclerotic 
cardiovascular disease, renovascular disease, diabetes, and 
acute gouty arthritis.62 Patients with chronic renal insuf-
ficiency are also at risk of acute vasomotor decline in renal 
function with NSAIDs. Typical clinical features include the 
presence of risk factors, modest salt and water retention, 
decreased urinary output, a benign urine sediment, low FENa 
(less than 1%), and prompt improvement in renal function 
upon discontinuation of NSAIDs.63,64
Several of the NSAIDs have been associated with an 
acute allergic interstitial nephritis that is highlighted by renal 
failure, heavy proteinuria, and interstitial nephritis with foot 
process fusion (minimal change) on renal biopsy. This renal 
failure with NSAIDs is also generally reversible, but in a 
slower fashion. Most drug-related reports of acute interstitial 
nephritis (AIN) have been with the use of penicillin and, 
in particular, its synthetic analogs such as methicillin. The 
antibiotic-induced acute allergic interstitial nephritis may 
have the clinical findings of a hypersensitivity reaction with 
fever, rash, joint pain, and eosinophilia. The urinary sediment 
is not diagnostic showing mild proteinuria (,1.5 g/24 hours), 
pyuria, hematuria, and granular casts. Urine cultures are 
usually negative. In general, recovery occurs with treatment 
of the underlying disease or removal of the offending drug. 
However, there have been reports of permanent impairment 
of renal function or death.65 The use of steroid therapy is 
controversial since there is no large randomized prospective 
controlled study indicating a beneficial effect of steroids.66 
However, a brief course of corticosteroids can hasten the 
recovery of renal function.66 Despite the lack of scientific 
evidence, a short course of prednisone in a patient whose 
renal function fails to improve within one week of stopping 
the inciting drug is recommended provided the diagnosis of 
AIN is confirmed by renal biopsy.66
Angiotensin converting enzyme (ACE) inhibitors and 
angiotensin II receptor blockers (ARBs) are widely used for 
the treatment of hypertension, chronic kidney disease, and 
congestive heart failure. The side effects are related directly 
or indirectly to reduced angiotensin II formation. AKI may 
occur in conditions where angiotensin plays a crucial role in 
maintaining GFR such as volume depletion, bilateral renal 
artery stenosis, polycystic kidney disease, heart failure, and 
cirrhosis. Diuretic-induced sodium depletion and underlying 
chronic renal insufficiency are major predisposing factors. 
Renal insufficiency is usually asymptomatic, nonoliguric, and 
associated with hyperkalemia. Since angiotensin II levels are 
rapidly reduced, the rise in the serum creatinine   concentration 
Table 6 Urine findings in prerenal azotemia and intrinsic AKI
Laboratory test Prerenal azotemia ATN
Urine sodium (UNa), meq/L ,20 .40
Urine osmolality, mOsm/kg H2O .500 ,400
Urine to plasma urea nitrogen .8 ,3
Urine to plasma creatinine .40 ,20
Fractional excretion of filtered sodium ,1 .1
Urinary sediment Bland “Muddy” brown granular 
casts, cellular debris, tubular 
epithelial cellsInternational Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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generally begins a few days after the institution of therapy. 
Thus, renal function should be checked at three to five days 
when an ACE inhibitor is begun in a patient who is at risk 
for AKI.
AKI occurs in up to 80% of patients receiving ampho-
tericin B especially when cumulative doses reach 3–4 g. 
Clinical features are similar to aminoglycosides. In addition, 
sodium, potassium, and magnesium wasting in the urine may 
occur. Patient hydration and liposomal forms of the drug 
have reduced AKI.67
The use of the calcineurin inhibitors (CNI), cyclosporine 
and tacrolimus, has led to major advances in the field of 
transplantation with excellent short-term outcome.   Currently, 
94% of kidney transplant recipients are discharged after 
transplantation with a CNI-based immunosuppressive regi-
men. CNIs can result in acute or chronic renal dysfunction. 
The acute renal dysfunction is due to vasoconstriction due 
to an imbalance of vasodilator factors like prostacyclin, 
prostaglandin E2, and nitric oxide and vasoconstrictor factors 
like endothelin and thromboxane. Acute renal dysfunction 
due to CNIs is usually reversible with discontinuation or 
reduction in dose.
Rhabdomyolysis
Rhabdomyolysis is a syndrome characterized by striated 
muscle necrosis and the release of intracellular muscle con-
stituent like myoglobin into the circulation. AKI is a potential 
complication of severe rhabdomyolysis. Patients with acute 
rhabdomyolysis usually present with pigmented granular 
casts, reddish-brown urine supernatant, and markedly raised 
serum creatine kinase. AKI associated with rhabdomyolysis 
often leads to a more rapid increase in plasma creatinine 
and lower ratio of BUN to creatinine than do other forms of 
AKI. Another characteristic feature is the frequent, but not 
universal, presence of a low FENa (,1%), perhaps reflecting 
the primacy of preglomerular vasoconstriction and tubular 
occlusion rather than tubular necrosis.68
Acute uric acid nephropathy
Acute uric acid nephropathy causes oliguric or anuric AKI 
due to intratubular precipitation of uric acid crystals. This 
is most often due to overproduction and overexcretion of 
uric acid in patients with lymphoma, leukemia, or a myelo-
proliferative disease such as polycythemia vera, particularly 
after chemotherapy or radiation has induced rapid cell 
lysis.   Clinical features are hyperuricemia (.15 mg/dL or 
893 µmol/L), hyperkalemia, hyperphosphatemia, and an 
increased uric acid-to-creatinine ratio (.1.0 mg/mg) on a 
random urine specimen; in comparison, the value is below 
0.60–0.75 in most other forms of AKI.69 Preventive measures 
include vigorous hydration and alkaline diuresis. Allopurinol 
should be started several days before the chemotherapy. 
The drug, rasburicase, which is the recombinant form of 
the enzyme uricase that converts uric acid to allantoin, has 
recently been Food and Drug Administration approved for 
the prevention and treatment of tumor lysis syndrome.
Acute phosphate nephropathy
Administration of oral sodium phosphate solution as bowel 
preparation for colonoscopy has recently been recognized as 
a cause of AKI.70 Risk factors for the development of acute 
phosphate nephropathy include preexisting chronic kidney 
disease, inadequate hydration, older age, hypertension treated 
with ACE inhibitors, ARBs or loop diuretics, female gender, 
and NSAIDs. Oral phosphate solution is contra-indicated 
in patients with chronic kidney disease, congestive heart 
failure, gastrointestinal obstruction, and preexisting elec-
trolyte disorders like hypercalcemia. Recently, five criteria 
have been proposed to make a diagnosis of acute phosphate 
nephropathy:70 1) AKI, 2) recent exposure to oral phosphate, 
3) renal biopsy findings of acute and chronic tubular injury 
with abundant calcium phosphate deposits (usually involv-
ing more than 40 tubular lumina in a single biopsy), 4) no 
evidence of hypercalcemia, and 5) no other significant pattern 
of renal injury on renal biopsy.
Management of AKI
Successful management of AKI requires early recognition of 
the diagnosis, investigation of the causes of AKI, management 
of complications, timely RRT, prevention of ongoing kidney 
injury, aggressive supportive care, and correction of the pri-
mary disorders. Despite many advances in the therapy of AKI, 
mortality rates remain constant at about 50–80%.
Fluids
The best way to monitor the adequacy of fluid replacement 
therapy is a clinical examination of extracellular fluid volume 
status, urine output, and daily weights. The goal is to achieve 
and maintain euvolemia while restoring effective circulat-
ing volume to allow adequate tissue and kidney perfusion. 
  However, optimal hemodynamic targets for resuscitation are 
not well defined. Isotonic saline is the appropriate replacement 
fluid for plasma losses (eg, burns, pancreatitis). The Saline 
versus Albumin Fluid Evaluation (SAFE) trial compared the 
use of either 4% albumin or normal saline for fluid resuscita-
tion in ICU patients.71 At 28 days, there was no   significant International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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difference noted between the two groups with respect to the 
primary outcome of death or secondary outcomes of organ 
failure, need for RRT, or duration of hospitalization. Of the 
patients with severe sepsis, mortality was 30.7% in those 
assigned to receive albumin and 35.3% in patients assigned 
to receive normal saline (P = 0.09). The study also concluded 
that whether saline or albumin confers benefit in a subgroup 
of critically ill patients merits further study.
Serum K+ and acid-base status should be monitored 
in all subjects. K+ supplementation of replacement fluids 
should not be given unless there is hypokalemia for example, 
sodium bicarbonate induced hypokalemia during treatment 
of metabolic acidosis.
Diuretics
Diuretics may be useful in volume overload in AKI. Nono-
liguric patients with AKI fare better than oliguric patients.72 
However conversion of oliguria to nonoliguria has not been 
shown to decrease mortality. Diuretics have not been shown 
to prevent AKI or improve outcomes in AKI.73 In fact, in a 
multicenter retrospective study of 552 patients with AKI in 
the ICU, diuretics were used in 326 patients (59%) at the time 
of nephrology consultation and with adjustment for relevant 
covariates and propensity scores, diuretic use was associated 
with a significant increase in the risk of death or nonrecovery 
of renal function.74
Nutritional support
Parenteral nutrition compared to other modalities of nutrition 
in critically ill patients has not been proven to be of benefit. 
With multiorgan dysfunction uremia is known to accelerate 
catabolism due to a variety of factors including acidosis, altered 
counter-regulatory hormonal status, and insulin resistance. 
A prospective double-blind study randomizing 30 patients 
with AKI to three isocaloric regimens: glucose alone, glu-
cose plus essential amino acids, or glucose plus essential and 
non-  essential amino acids has been performed.75 All patients 
remained in negative nitrogen balance and remained so through-
out the study and no difference in recovery of renal function or 
survival between treatment groups was noted. In patients on 
continuous RRT, despite an intake of 2.5 g/kg/day of protein, 
these patients remained in negative nitrogen balance.76
In recent reviews of the topic, the following recommenda-
tions were made: 1) protein and non protein calories should 
be provided to meet calculated energy expenditures and at a 
rate not to exceed 1.5 g/kg/day protein intake, 2) nutritional 
recommendations should not be different from that of 
critically ill patients as a whole, 3) total parentral nutrition 
should be administered only to patients who are severely 
malnourished or patients expected to be unable to eat for 
greater than 14 days, and 4) enteral feeding is the preferred 
means of nutritional supplementation.77
Specific therapies for AKI
Although the mortality in patients with AKI has declined 
between 1988 and 2002,78 the mortality of AKI in the ICU 
remains high.79 Most interventional therapeutic trials in AKI 
eg, furosemide,80 dopamine and furosemide,81 anaratide,82,83 
insulin-like growth factor-1,84 and fenoldopam85 have failed 
in humans. A possible reason for the failure of interven-
tional trials in AKI is the dependence on serum creatinine 
to diagnose AKI. Alterations in serum creatinine may lag 
24–48 hours behind actual changes in GFR.7,8 Ideally, in 
the future, early diagnosis of AKI using urine or plasma 
biomarkers may allow early initiation of specific therapies 
eg, erythropoietin to treat or prevent worsening of AKI.
Renal replacement therapies
In the presence of AKI complications such as hypervolemia 
eg, acute pulmonary edema or large cumulative positive fluid 
balance, hyperkalemia, metabolic acidosis (pH less than 7.1) 
and uremic symptoms (persistent nausea and vomiting, peri-
carditis, neuropathy, or an otherwise unexplained decline in 
mental status) dialysis should be considered as a mainstay 
therapy. Modalities of RRT include intermittent hemodialysis 
(IHD), continuous renal replacement therapies (CRRTs), 
and hybrid therapies, such as sustained low-efficiency 
dialysis (SLED). Despite these varied techniques, mortality 
in patients with AKI remains greater than 50% in severely ill 
patients. It is possible that variations in the timing of initia-
tion, modalities, and/or dosing of RRT may affect clinical 
outcomes, particularly survival.
The main considerations when starting a patient with AKI 
on dialysis are the following: 1) timing of initiation of   dialysis, 
2) the modality of dialysis, and 3) dose of dialysis.
Timing of initiation of dialysis
Recently, studies have evaluated the relationship between 
the timing of CRRT initiation and clinical outcomes. In a 
retrospective study of a single trauma unit, patients were 
characterized as “early” or “late” starters, based on a BUN of 
less than or greater than 60 mg/dL, prior to CRRT   initiation. 
Survival was 39% in early starters compared to 20% in late 
starters (P = 0.041).86 Two analyses of patients develop-
ing AKI following cardiac surgery demonstrated higher 
survival rates in patients in whom continuous   veno-venous International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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  hemofiltration (CVVH) was initiated in response to a urine 
output of less than 100 mL within eight hours consecutively 
after surgery despite diuretic administration, compared to 
patients in whom therapy was withheld until objective labo-
ratory criteria using serum creatinine, BUN, and potassium 
were present.87,88 In 243 patients from the Program to Improve 
Care in Acute Renal Disease (PICARD) study, the risk of 
death was determined in patients with a BUN of greater 
than or less than 76 mg/dL at the initiation of dialysis. After 
adjustment for age, hepatic failure, sepsis, thrombocytopenia, 
and serum creatinine and stratified by site and initial dialysis 
modality, the relative risk for death was 1.85 (95% confidence 
interval 1.16–2.96) for the patients with a BUN greater than 
76 mg/dL.89 This study provides the rationale for prospective 
trials of the early initiation of RRT in AKI patients.
Modality of dialysis
Several retrospective and prospective studies have compared 
outcomes for continuous versus intermittent modalities. 
In general, studies are difficult to perform as sicker (eg, severely 
hypotensive patients are generally started on CVVH) and less 
sick (eg, mobile, non hypotensive patients are generally started 
on IHD). In a retrospective study of 349 patients, the mortality 
rate was higher for continuous versus intermittent dialysis (68% 
versus 41%, P , 0.001).90 However, when multivariate cox 
analysis was used to adjust for reasons for patient assignment 
to continuous treatment (eg, systolic blood pressure less than 
90 mmHg, liver failure etc) there was no increase in risk of 
death with continuous treatment. In another prospective study, 
225 patients in the ICU were divided into three groups: group I 
(control group): 156 patients with AKI who did not receive 
dialysis, group II: 21 patients that received IHD or peritoneal 
dialysis, and group III: 43 patients that received continuous 
hemodiafiltration. The mortality was higher in patients with 
renal failure that required dialysis. There was no difference in 
mortality between patients that required IHD versus CRRT.91
A multicenter, randomized, controlled trial was con-
ducted comparing IHD and continuous hemodiafiltration 
in the ICU.92 The 166 patients were randomized. Principal 
outcome measures were ICU and hospital mortality, length 
of stay, and recovery of renal function. Despite randomiza-
tion, there were significant differences between the groups 
in several covariates independently associated with mortal-
ity, including gender, hepatic failure, Acute Physiology and 
Chronic Health Evaluation II and III scores, and the number 
of failed organ systems, in each instance biased in favor of 
the intermittent dialysis group. Using logistic regression to 
adjust for the imbalances in group assignment, the odds of 
death associated with continuous therapy was not different 
  compared to IHD. In the most recent study of intermittent 
versus continuous dialysis in 316 critically ill patients, the 
modality of RRT had no effect on outcome.93 In a meta-
analysis of 1,635 patients from nine randomized control trials, 
it was concluded that CRRT does not confer a survival advan-
tage over IHD.94 In conclusion, it is recommended that the 
modality of dialysis be tailored to the individual patient.
A new hybrid technique is named SLED in which stan-
dard IHD equipment is used with reduced dialysate and blood 
flow rates. In a single center study, 12-hour treatments were 
performed nocturnally, allowing unrestricted access to the 
patient for daytime procedures and tests.95 The 145 SLED 
treatments were performed in 37 critically ill patients for 
whom IHD had failed or been withheld. The study concluded 
that SLED is a viable alternative to traditional continuous 
RRTs for critically ill patients in whom IHD has failed due 
to hypotension or been withheld.95
Dose of dialysis
Three recent single center studies have demonstrated 
that increased dose of dialysis is associated with a lower 
  mortality. A prospective randomized study of the effect of dif-
ferent ultrafiltration doses in CRRT on survival has recently been 
performed.96 A total of 425 patients in ICU, with a mean age of 
61 years, who had AKI were studied. Patients were randomly 
assigned ultrafiltration at 20 mL/hr/kg (group 1, n = 146), 35 mL/
hr/kg (group 2, n = 139), or 45 mL/hr/kg (group 3, n = 140). 
The primary endpoint was survival at 15 days after stopping 
hemofiltration. Survivors in all groups had lower concentrations 
of BUN before continuous hemofiltration was started than non-
survivors. The frequency of complications was similarly low in 
all groups. Mortality among these critically ill patients was high, 
but patients receiving the higher dose of ultrafiltration (groups 
2 and 3) had significantly improved survival. In another study, 
160 patients with ARF were assigned to receive daily or alternate 
day IHD. The mortality rate, according to the intention-to-treat 
analysis, was 28% for daily dialysis and 46% for alternate-day 
dialysis (P = 0.01).97 The hypothesis that an increase in dialysis 
dose obtained by using continuous veno-venous hemodiafiltra-
tion (CVVHDF) is associated with a better survival than CVVH 
was tested in 206 patients.98 Twenty eight day and three month 
survival was significantly higher in the CVVHDF group that 
received an increased dose of dialysis. In view of the promis-
ing single center studies, a large multicenter study, the ATN 
study, was performed by the Veteran’s Administration/National 
Institues of Health ARF Trial   network.99 In 1,124 critically ill 
patients with AKI,   intensive renal support did not decrease International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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  mortality, improve recovery of kidney function, or reduce the 
rate of nonrenal organ failure as compared with less-intensive 
therapy. The RENAL (Randomised Evaluation of Normal ver-
sus Augmented Level of Replacement Therapy) is the largest 
interventional trial in AKI patients. The 1,502 patients were ran-
domized to receive CVVH with effluent flow of 40 mL/hour/kg 
(high intensity) or 25 mL/hour/kg (low intensity).100 At 90 days 
after randomization, the mortality was the same in both groups 
−44.7% at 90 days. There were 6.8% of the survivors of the 
high intensity group compared to 4.5% of the survivors of the 
low intensity group still on CVVH at 90 days (P = 0.14). In an 
editorial on the ATN and RENAL studies,101 it was concluded 
that 1) the failure to demonstrate improved outcomes with more 
intensive RRT does not imply that the intensity of RRT does 
not matter,101 2) a minimal dosing threshold must be achieved 
to obtain optimal clinical outcomes (eg, in the ATN study, each 
HD was dosed to have a Kt/V of .1.2. In the RENAL study, 
CVVH was dosed per body weight and blood flow was kept 
above 150 mL/min), and 3) in practice, dialysis should be dosed 
for the individual patient. The studies examining the dose of 
dialysis in AKI are listed in Table 7.
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